Bird Flu: 100 Million Doses of Vaccine Could Be Shipped Within Months – Healthline
							May 9, 2024
							      The H5N1 bird flu circulating in the U.S. remains far more      dangerous for birds than for people.    
      Currently, this strain of the flu that circulated in cows has      led to just a single person being affected in the last few      months. But the strain of influenza has the potential to      mutate, so federal health officials are already thinking      ahead toward a potential vaccine.    
      The country has two candidate vaccine viruses available to      manufacturers for the production of a bird flu vaccine, the      Centers for Disease Control and Prevention (CDC) said on its      website.    
      These [candidate vaccine viruses] are like seed stock that      are kept in reserve in case there is an outbreak of that      particular strain, said David Diemert, MD, a professor      of medicine in the School of Medicine and Health Sciences at      George Washington University, and director of the GW Vaccine      Research Unit.    
      If bird flu started easily spreading to people, [the      candidate vaccine virus] can be sent to manufacturers to make      millions of doses of vaccine, he said, using the existing      hen egg technology that we normally use for the regular      seasonal vaccine.    
      A candidate      vaccine virus is attenuated, or weakened version of the      virus. As a result, it is unlikely to lead to active      infections in people who get the vaccine.    
      This type of weakened virus is able to grow well in hen eggs,      which is what most manufacturers use to produce seasonal flu      vaccine.    
      The candidate vaccine would also have the surface proteins       known as hemagglutinin  of the virus circulating in the      community. This enables a vaccine to generate a protective      immune response.    
      The U.S. National Pre-Pandemic Influenza Vaccine Stockpile      (NPIVS) has four types of H5N1 candidate vaccine viruses,      reported STAT News. The bird      flu affecting dairy cows is a strain of H5N1.    
      Only two of these candidate vaccine viruses are a good match      for the currently circulating strain of bird flu.    
      Studies suggest that vaccines based on these two candidate      vaccine viruses will offer good cross-protection against      cattle outbreak viruses, Demetre Daskalakis, director of the      National Center for Immunization and Respiratory Diseases,      said on a call on May 1.    
      However, Amesh      Adalja, MD, senior scholar at the Johns Hopkins Center      for Health Security at the Bloomberg School of Public Health,      cautioned that the candidate vaccine viruses are not a      perfect match for the currently circulating strain of H5N1.      This means they may not produce vaccines very effective at      preventing disease.    
      In addition, research done      in the mid-2000s found that H5N1 vaccines dont trigger a      strong immune response in people unless it is given in a      large enough dose; or if it is given with a compound known as      an adjuvant, which boosts the immune response.    
      Adalja pointed out that the H5N1 vaccines that we have in the      stockpile are really not that good at provoking an immune      response.    
      Even for the viruses they are targeted against, said      Adalja. In clinical trials, the protective antibody levels      that people had were modest.    
      One of these existing H5N1 vaccines in the NPIVS is      made by CSL Seqirus, which supplies flu vaccine to the U.S.      market.    
      Still, Diemert thinks a bird flu vaccine based on the two      candidate vaccine viruses in the NPIVS would be effective and      potentially more effective than seasonal influenza vaccines.    
      This is because a bird flu vaccine would likely only have to      target a single virus strain.    
      In contrast, during seasonal flu season, there may be      multiple strains of influenza that spread. Seasonal      flu vaccines are developed to target certain strains of      influenza every year. The vaccines are developed in the      summer and early fall by looking at common strains in the      Southern Hemisphere. But during flu season the strains that      become more common in North America may not be the strains      the vaccine was primed to target.    
      As a result, seasonal flu vaccines may end up targeting      strains of influenza      virus that are not the ones in circulation that year.    
      Thats one of the reasons that [seasonal flu vaccines] are      not 100% effective because theyre not a perfect match, said      Diemert.    
      Before bird flu vaccines could be rolled out, they would need      to be approved by the Food and Drug Administration (FDA) but      the agency has a process for approving updated      seasonal flu vaccines each year.    
      So this should go fairly smoothly, said Diemert, especially      since the [bird flu] vaccines would be made using the same      manufacturing process that they use every year [for seasonal      flu vaccines].    
      Also, Im sure if there was a massive outbreak of this      particular strain, then the FDA would speed things up, he      said. So I dont see regulatory approval being a      rate-limiting step.    
      In terms of getting the vaccine to the people who need it the      most, all of the pieces are in place to be able to roll out      a vaccine relatively quickly, said Diemert.    
      However, when you send [the candidate vaccine virus] to the      manufacturer, it still takes weeks to months to make all the      doses you need, he said.    
      This is especially difficult in a fast-moving situation      such as a pandemic, said Peter Chin-Hong, MD, an      infectious disease physician at UCSF Health.    
      Federal health officials estimate that over 100 million doses could      be shipped within three to four months. However, they expect      people to need two doses, so this would only cover 50 million      people.    
      Vaccine production could also be affected by the same virus      the vaccine would be designed to protect against.    
      Manufacturers most often use hen eggs to produce flu      vaccines, but chickens are also susceptible to the bird flu      virus that is affecting cattle.    
      So, if you have a global [influenza] pandemic, and you have      birds dying too, that may constrain supplies such as chicken      eggs, said Adalja.    
      As of May 6, over 5 million chickens and      other commercial or backyard poultry birds in the United      States have been affected by highly pathogenic avian influenza (HPAI). which      includes H5N1, reports the U.S. Department of Agriculture.    
      The big question is whether enough vaccine doses could be      rolled out in time to make a difference.    
      With the 2009 H1N1 pandemic, by the time the vaccine came      out, the pandemic had already dissipated, said Chin-Hong.    
      During that outbreak, tens of millions of Americans      were vaccinated, but by the time the vaccine doses were      available, the fall wave had subsided.    
      However, this is 2024 and things have changed, said      Chin-Hong, referring to the fast development and rollout of      the COVID-19 vaccines. When people put their mind to it, it      could be done fast  But the devil is in the details.    
      Overall, its going to take some time to actually gear up to      be able to vaccinate everybody whos at risk for flu, said      Adalja. And as I said, the candidate vaccine virus that is      stockpiled is not a perfect match. And even if it were a      perfect match, [the H5N1 vaccine] is not a great vaccine to      begin with.    
      Federal health officials said the government is also pursuing      an mRNA bird flu vaccine, based      on the same technology as Pfizers and Modernas COVID-19      vaccines.    
      Chin-Hong said this type of vaccine could potentially be      updated more quickly to match the currently circulating      strains of the virus. But these vaccines have their own      challenges, he said, such as needing to be stored at      extremely cold temperatures.    
      In addition, given that these vaccines would be a new use of      the mRNA vaccine technology, the FDA may require clinical      trials which could delay the roll-out to the greater      population.    
      There are other options for dealing with an outbreak of bird      flu in people, including antivirals such as Tamiflu, which      would be given to people who are already infected.    
      Different interventions speak to different people, said      Chin-Hong. In general, Americans prefer to treat something      rather than prevent it, which can be a challenge.    
      As seen during the COVID-19 pandemic, its not just how many      vaccine doses you can ship that matters, but also how many      people receive the vaccines.    
      The problem we may have is that there is more vaccine      hesitancy now, so people may not be as willing to get      vaccinated, said Diemert. I dont know if that will be      different because the [hen egg] flu vaccine technology has      been around for decades and theres a lot of evidence of its      safety.    
      Chin-Hong pointed to the poor current COVID-19 vaccination      rates among American adults as a sign of vaccine fatigue.    
      Around 22% of all American adults have received the updated      COVID-19 vaccine, with a slightly better rate (38%) among      older adults, according to the CDC. Both      rates are much lower than health officials would like to see.    
      That shows how fatigued people are [with vaccination      campaigns], said Chin-Hong. This [hesitancy] would need to      be addressed in the same breath as having a well-oiled plan      [for rolling out the vaccines].    
      Adalja is concerned not just about vaccine hesitancy, but      with growing public opposition to vaccines, in general.    
      In 2009 with H1N1, vaccination uptake was subpar because      concerns raised by the anti-vaccine community  which were      unwarranted concerns  dissuaded people from getting      vaccinated, he said.    
      But after COVID-19, the anti-vaccine movement is more      powerful than it has been in decades, he added. So I think      mounting a vaccination campaign in an [future] emergency is      going to be very difficult to do in the current political      environment.    
      There is no sign that the H5N1 bird flu circulating in dairy      cow herds is developing the ability to spread easily to      people. But federal health officials are planning for the      rollout of a bird flu vaccine as a precaution.    
      The federal government has two candidate vaccine viruses      stockpiled. These are weakened so they cannot infect people      or cause illness, but they grow well in hen eggs, which is      how flu vaccine are most often made.    
      The candidate vaccine viruses are not a perfect match for      the bird flu virus currently circulating, but they should      offer good protection, say health officials. However, experts      are concerned that vaccine fatigue will deter uptake.    
See the original post: 
Bird Flu: 100 Million Doses of Vaccine Could Be Shipped Within Months - Healthline